Foundation for Innovative New Diagnostics, Geneva, Switzerland.
Int J Tuberc Lung Dis. 2010 Feb;14(2):243-6.
Culture and drug susceptibility testing results of 2816 tuberculosis (TB) patients from across India who had failed repeated treatments from 2001 to 2004 were retrospectively analysed at the Tuberculosis Research Centre, Chennai. Of 1498 (53%) identified as having multidrug-resistant TB (MDR-TB), 671 (44.8%) were resistant to > or =1 second-line drugs (SLDs): 490 (32.7%) to ethionamide, 245 (16.4%) to ofloxacin and 169 (11.3%) to kanamycin; 69 (4.6%) were extensively drug-resistant TB (XDR-TB). Although from a highly select and non-representative patient group, such high SLD resistance levels, including XDR-TB, among MDR-TB patients is of concern. The prevention of MDR/XDR-TB through quality DOTS services, however, remains the priority. In addition, rapid scale-up of quality programmatic management under the RNTCP is needed, with more control and rational use of SLDs outside the programme.
对来自印度各地的 2816 名在 2001 年至 2004 年期间多次治疗失败的结核病(TB)患者的文化和药敏试验结果进行了回顾性分析,这些患者均来自于钦奈的结核病研究中心。在 1498 名(53%)被确定为耐多药结核病(MDR-TB)的患者中,有 671 名(44.8%)对≥1 种二线药物(SLD)耐药:490 名(32.7%)对乙胺丁醇耐药,245 名(16.4%)对氧氟沙星耐药,169 名(11.3%)对卡那霉素耐药;69 名(4.6%)为广泛耐药结核病(XDR-TB)。尽管这些患者来自一个高度选择且非代表性的患者群体,但 MDR-TB 患者中的 SLD 耐药水平如此之高,包括 XDR-TB,这令人担忧。然而,通过高质量的直接督导下的短程化疗(DOTS)服务预防 MDR/XDR-TB 仍然是首要任务。此外,还需要在 RNTCP 下快速扩大质量方案管理,加强对方案外 SLD 的控制和合理使用。